Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PCT3 refers to the total saponins extracted from the medicinal plant *Paris forrestii* (Takht.) H. Li, a species native to high-altitude regions of Tibet and Yunnan, China. This botanical extract contains a complex mixture of steroid glycosides that have demonstrated significant antineoplastic activity in preclinical models of acute myeloid leukemia (AML), prostate cancer, and breast cancer. PCT3 exerts its effects by inducing apoptosis through the endogenous pathway, involving the activation of Caspase-3 and the modulation of Bcl-2 family proteins (downregulating Bcl-2 and Mcl-1 while upregulating Bax). Furthermore, it has been identified as a potential agent for reversing multidrug resistance (MDR) in cancer cells by downregulating the expression of the efflux pump P-glycoprotein (P-gp) via the inhibition of the ERK signaling pathway.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PCT3.